Evidence map›Paper›PMID 40527060›Full record

ArticleVaccine2025

Genetic markers of enhanced functional antibody responses to COVID-19 vaccination.

Ruth A Purcell, L Carissa Aurelia, Lilith F Allen, Katherine A Bond, Deborah A Williamson, Janine M Trevillyan, Jason A Trubiano, Bruce D Wines, P Mark Hogarth, Jennifer A Juno and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Ruth A PurcellDepartment of Microbiology and Immunology, The Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, VIC 3000, Australia.
L Carissa AureliaDepartment of Microbiology and Immunology, The Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, VIC 3000, Australia.
Lilith F AllenDepartment of Microbiology and Immunology, The Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, VIC 3000, Australia.
Katherine A BondDepartment of Microbiology and Immunology, The Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, VIC 3000, Australia; Victorian Infectious Diseases Reference Laboratory (VIDRL), The Peter Doherty Institute for Infection and Immunity, Melbourne, VIC 3000, Australia.
Deborah A WilliamsonDepartment of Infectious Diseases, The Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, VIC 3000, Australia; School of Medicine, University of St Andrews, Fife, KY16 9TF, Scotland.
Janine M TrevillyanDepartment of Infectious Diseases, The Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, VIC 3000, Australia; Centre for Antibiotic Allergy and Research, Austin Health, Heidelberg, VIC 3084, Australia.
Jason A TrubianoCentre for Antibiotic Allergy and Research, Austin Health, Heidelberg, VIC 3084, Australia; Department of Medicine, University of Melbourne, Parkville, VIC 3010, Australia; Department of Infectious Diseases, Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia; National Centre for Infections in Cancer, Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia.
Bruce D WinesImmune Therapies Group, Burnet Institute, Melbourne, VIC 3004, Australia; Department of Immunology and Pathology, Central Clinical School, Monash University, Melbourne, VIC 3004, Australia.
P Mark HogarthImmune Therapies Group, Burnet Institute, Melbourne, VIC 3004, Australia; Department of Immunology and Pathology, Central Clinical School, Monash University, Melbourne, VIC 3004, Australia; Department of Clinical Pathology, University of Melbourne, Melbourne, VIC 3000, Australia.
Jennifer A JunoDepartment of Microbiology and Immunology, The Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, VIC 3000, Australia.
Adam K WheatleyDepartment of Microbiology and Immunology, The Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, VIC 3000, Australia.
Thi H O NguyenDepartment of Microbiology and Immunology, The Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, VIC 3000, Australia.
Kanta SubbaraoDepartment of Microbiology and Immunology, The Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, VIC 3000, Australia; WHO Collaborating Centre for Reference and Research on Influenza, The Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, VIC 3000, Australia.
Katherine KedzierskaDepartment of Microbiology and Immunology, The Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, VIC 3000, Australia.
Stephen J KentDepartment of Microbiology and Immunology, The Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, VIC 3000, Australia; Melbourne Sexual Health Centre and Department of Infectious Diseases, Alfred Health, Central Clinical School, Monash University, Melbourne, VIC 3004, Australia.
Siddhartha MahantyDepartment of Infectious Diseases, The Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, VIC 3000, Australia.
Kevin John SelvaDepartment of Microbiology and Immunology, The Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, VIC 3000, Australia.
Amy W ChungDepartment of Microbiology and Immunology, The Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, VIC 3000, Australia. Electronic address: awchung@unimelb.edu.au.

Funding

NIH HHS HHSN272201400005C
6 · The paper itself

Abstract

introductionSubstantial population-level variation in vaccine-specific antibody responses has been observed following global coronavirus disease 2019 (COVID-19) vaccination efforts. Beyond the influence of clinical and demographic features, immunogenetic variation is suggested to underlie divergent serological responses following COVID-19 vaccination of distinct populations.

methodsImmunoglobulin G1 (IgG1) allotypic markers (G1m) for 121 COVID-19 vaccinated healthy adults were genotyped via Sanger sequencing. Vaccine-specific IgG and Fc gamma receptor (FcγR) engagement were characterised via bead-based multiplex array.

resultsFollowing two COVID-19 vaccine doses, G1m1,17

conclusionPrimary COVID-19 vaccination induced increased S2-specific IgG in G1m1,17

Indexed as

Antibodies, ViralAntibody FormationCOVID-19COVID-19 VaccinesSARS-CoV-2AdultFemaleGenetic MarkersHumansImmunoglobulin GMaleMiddle AgedReceptors, IgGSpike Glycoprotein, CoronavirusVaccinationYoung AdultAntibodies, ViralCOVID-19 VaccinesGenetic MarkersImmunoglobulin GReceptors, IgGSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2Fc functionsFcγR polymorphismIgG AllotypeImmunogeneticsSARS-CoV-2Vaccine

Identifiers

PMID40527060
PMCPMC13223335

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.